Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer

REHOVOT, Israel, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Todos Medical, Ltd. Inc. (OTCQB:TOMDF) (www.todosmedical.com), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced today the hiring of a new CFO, Mr. David Ben Naim, CPA, MBA.

Mr. Ben Naim has a distinguished record as Chief Financial Officer for companies listed in both the United States and Israel. Since 2014, Mr. Ben Naim has owned and managed DBN Finance which provides full outsourcing financial services to companies located in Israel. Prior to that, Mr. Ben Naim was the CFO at Insuline Medical Inc (TASE - INSL) where he reported directly to the CEO and worked closely with the board of directors and its various committees. Mr. Ben Naim has also served in the role of CFO for Crow Technologies (OTCQB - CRWTF) and Ilex Medical Limited (TASE). Other positions held by Mr. Ben Naim include CFO of Microbot Medical (NASDAQ - MBOT) and Vonetize PLC (TASE - VNTZ). Additionally, Mr. Ben Naim held the title of Corporate Controller at Tadiran Telecom Limited. Mr. Ben Naim earned an MBA from Ono Academic College as well as a C.P.A. license from Ramat Gan College.

“We are very pleased Mr. David Ben Naim has joined the Todos Medical team. David has a wealth of experience dealing with public companies and he will be a true asset to the team,” said Rami Zigdon, CEO of Todos Medical.

About Todos Medical

Todos Medical Ltd. (OTCQB: TOMDF) an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic (“IVD”) company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.

For more information, the content of which is not part of this press release, please visit http://www.Todosmedical.com.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our expected clinical development programs and clinical trials. These forward-looking statements are only based on the current expectations of the management of Todos Medical, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, reference is made to Todos Medical’s reports filed from time to time with the U.S. Securities and Exchange Commission.

Media Contact:

Todos Medical Ltd.
Daniel Hirsch
Investor Relations
(347) 699-0029


Source:Todos Medical Ltd.